ial
statements for the year ended December 31, 2007, which have been prepared
in accordance with Canadian Generally Accepted Accounting Principles
(GAAP). For discussion regarding related-party transactions, contractual
obligations, disclosure controls and procedures, internal control over
financial reporting, critical accounting policies and estimates, recent
accounting pronouncements, and risks and uncertainties, refer to the Annual
Report and the Annual Information Form for the year ended December 31,
2007, as well as registration statements and other public filings, which
are available on SEDAR at
http://www.sedar.com - or on EDGAR at
http://www.sec.gov. This
document contains forward-looking statements, which are qualified by
reference to, and should be read together with the "Forward-Looking
Statements" cautionary notice, which can be found at the end of this MD&A.
This MD&A was prepared by management with information available as of May
5, 2008.
As previously reported, effective July 1, 2007, the Company adopted the
US dollar as its functional and reporting currency, as a significant
portion of its revenue, expenses, assets, liabilities and financing are
denominated in US dollars. All currency figures reported in this document,
including comparative figures, are reported in US dollars, unless otherwise
specified.
Results of Operations
For the three-month period ended March 31, 2008, the net loss amounted
to $12,902,000 ($0.26 per share), compared to $21,016,000 ($0.54 per share)
for the corresponding period the previous year.
Revenue from collaboration agreement amounted to $205,000 for the
current quarter, compared to $373,000 for the same period the previous
year. This revenue was earned under the agreement with Centocor, Inc.
(Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational
product candidate for the treatment
'/>"/>
SOURCE BELLUS Health Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related medicine news :1.
At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)2.
Penn study finds pro-death proteins required to regulate healthy immune function3.
UCLA researchers identify markers that may predict diabetes in still-healthy people4.
Air pollution linked to cardiovascular risk indices in healthy young adults5.
More proof needed of safety and quality of electronic personal health records6.
Health care incentive model offers collaborative approach7.
Loneliness is bad for your health8.
Mailman School of Public Health study examines link between racial discrimination and substance use9.
Green Tea May Brew Up Healthier Skin 10.
For Health Info, Women Often Turn to the Web11.
Record Number of Americans Lack Health Insurance